IRIC - Institute for Research in Immunology and Cancer

Published on May 9, 2024

A collaborative research project between the teams of Guy Sauvageau, director of the IRIC Molecular Genetics of Stem Cells Research Unit, and Anne Marinier, CEO of biotech company RejuvenRx, recently received $3,697,199 in funding. The grant was made possible by investments from the Quebec Consortium for Drug Discovery (CQDM), the Quebec government, RejuvenRx, the Canadian Institutes of Health Research and the Université de Montréal Partenariat fund.

The project aims to develop new therapies against cellular aging, in particular by optimizing a series of molecules previously discovered at IRIC. Slowing down the aging of cells, and even rejuvenating them, could prove to be a concrete step forward in treating age-related diseases such as Alzheimer’s and Parkinson’s.

For full funding details, see the official announcement.